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ABSTRACT
Background The role of specific blood tests to predict 
poor prognosis in patients admitted with infection 
from SARS- CoV-2 remains uncertain. During the first 
wave of the global pandemic, an extended laboratory 
testing panel was integrated into the local pathway 
to guide triage and healthcare resource utilisation for 
emergency admissions. We conducted a retrospective 
service evaluation to determine the utility of extended 
tests (D- dimer, ferritin, high- sensitivity troponin I, lactate 
dehydrogenase and procalcitonin) compared with the 
core panel (full blood count, urea and electrolytes, liver 
function tests and C reactive protein).
Methods Clinical outcomes for adult patients with 
laboratory- confirmed COVID-19 admitted between 17 
March and 30 June 2020 were extracted, alongside costs 
estimates for individual tests. Prognostic performance 
was assessed using multivariable logistic regression 
analysis with 28- day mortality used as the primary 
endpoint and a composite of 28- day intensive care 
escalation or mortality for secondary analysis.
Results From 13 500 emergency attendances, we 
identified 391 unique adults admitted with COVID-19. 
Of these, 113 died (29%) and 151 (39%) reached the 
composite endpoint. ’Core’ test variables adjusted for 
age, gender and index of deprivation had a prognostic 
area under the curve of 0.79 (95% CI 0.67 to 0.91) 
for mortality and 0.70 (95% CI 0.56 to 0.84) for 
the composite endpoint. Addition of ’extended’ test 
components did not improve on this.
Conclusion Our findings suggest use of the extended 
laboratory testing panel to risk stratify community- 
acquired COVID-19 positive patients on admission 
adds limited prognostic value. We suggest laboratory 
requesting should be targeted to patients with specific 
clinical indications.
INTRODUCTION
In December 2019, COVID-19 was reported in 
China, caused by SARS- CoV-2.1 In the first year 
since its emergence, SARS- CoV-2 has caused over 
79 million infections and more than a 1.7 million 
deaths worldwide.2 The majority of patients 
with COVID-19 experience a mild influenza- 
like illness; however, approximately 15%–25% 
of those admitted to hospital develop pneumonia 
that may evolve into acute respiratory distress 
syndrome.3–6 Experience from the Italian region of 
Lombardy highlighted the potential of uncontrolled 
COVID-19 outbreaks to rapidly overwhelm local 
intensive care capacity and healthcare systems.5 
In the UK, Wales has one of the lowest number 
of intensive care beds per head of population in 
Europe,7 8 prompting implementation of scoring 
systems to support patient triage and allocation of 
healthcare resources.
The ability to identify patients at greatest risk 
of developing life- threatening complications from 
SARS- CoV-2 infection based on haematological 
and biochemical laboratory markers was suggested 
early in the pandemic. A range of admission 
tests including D- dimer, ferritin, high- sensitivity 
troponin I (hs- Trop) and lactate dehydrogenase 
(LDH) have been linked with disease severity and 
risk of death.9–13 Similar findings have been repli-
cated in meta- analysis.14 Furthermore, use of a 
broader range of laboratory tests in patients with 
COVID-19 has been supported by the UK Royal 
College of Pathologists15 and the International 
Federation of Clinical Chemistry (IFCC).16 Accord-
ingly, an extended panel of laboratory tests was 
integrated within the standard of care pathway for 
COVID-19 admissions presenting via the emer-
gency eepartment (ED) of the University Hospital 
of Wales. This panel consisted of both ‘core’ (full 
blood count (FBC), urea and electrolytes (U&E), 
liver function tests (LFTs) and C reactive protein 
(CRP)) and ‘extended’ test components (D- dimer, 
LDH, ferritin, hs- Trop and procalcitonin (PCT)).
A joint National Health Service (NHS)–Univer-
sity collaboration supporting the rapid creation of 
an electronic healthcare registry (see online supple-
mentary: extended methods) provided a timely 
opportunity to retrospectively assess the value and 
cost of implementing this extended laboratory 
panel. This is particularly relevant given a recent 
systematic review of methodological and reporting 
standards highlighting caution before extrapolating 
models and decision thresholds derived from prog-
nostic biomarker studies into local clinical prac-
tice.17 The role of extended components remains 
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poorly represented in prognostic studies within the UK popu-
lation to date.4 17–20 We therefore conducted a service evalua-
tion focusing on the ability of these tests to predict mortality or 
escalation to intensive care in the first 28 days following admis-
sion, in adult patients with PCR- confirmed COVID-19. Given 
extensive work in the existing literature concerning prognostic 
model development,21 we did not seek to develop an novel tool. 
Instead, our primary aim was to evaluate the additional value 
extended laboratory tests conferred to patient risk stratification 
when used in patients meeting nationally defined clinical admis-
sion criteria, relative to routine core tests. Our secondary aim 
was to explore the additional cost of extended testing compo-
nents. Together, we reveal limited prognostic value associated 
with use of extended laboratory tests, directing refinement of 
a risk stratification panel with potential cost savings ahead of 
future waves of COVID-19.
METHODS
Study population
We identified patients aged ≥18 years admitted between 
17 March 2020 and 30 June 2020 via the ED of the Univer-
sity Hospital of Wales (Cardiff, UK). This 1000- bed hospital 
is a tertiary referral centre within the region with the greatest 
recorded total of COVID-19 case positives in Wales.22 Only 
patients with SARS- CoV-2 infection confirmed by PCR on naso-
pharyngeal swab and likely community- acquired disease (defined 
as swab positive between 14 days prior or 7 days following the 
date of initial emergency attendance) were included. The criteria 
for admission were defined by the All- Wales COVID-19 Pathway 
for Secondary Care Management Guideline (available: https:// 
tinyurl. com/ all- wales- COVID- 19- guidelines), with hypoxia 
(peripheral oxygen saturations <94% on room air) the primary 
triage criteria for admission. Patients transferred in from other 
hospitals were excluded. The primary dataset was extracted as 
part of a service evaluation to assist local care planning. A fully 
anonymised dataset was created by a member of the Health 
Board NHS IT team. Prior to anonymisation, the postcode 
was used to extract the Welsh Index of Multiple Deprivation 
(WIMD) for each patient, as obtained from https:// wimd. gov. 
wales/. As such, ethical approval was not required for this study.
Data fields including admission date, clinical outcomes and 
laboratory measurements were integrated into an electronic 
healthcare registry ‘Cardiff Hospital Records Database - CHoRD’ 
using a bespoke software package: CHoRDBuilder (see online 
supplemental file 1: extended methods). Laboratory test results 
from the index presentation reported within the first 72 hours of 
ED presentation were considered as candidate variables.
Outcomes
Twenty- eight- day mortality was chosen as the primary endpoint 
in accordance with UK COVID-19 mortality reporting. To 
support generalisability between studies,4 18 we performed 
secondary analysis using the composite endpoint of 28- day 
mortality or admission to intensive care.
Laboratory testing panel
All testing was performed in the United Kingdom Accreditation 
Service- accredited Biochemistry, Immunology, and Haematology 
Laboratories at the University Hospital of Wales. Cost estimates 
were obtained from the Health Board Laboratory Medicine 
Directorate, reflecting consumables, reagent, analyser running 
and maintenance costs, and staff time chargeable to NHS test 
requestors.
Statistical analysis
Statistical significance testing was performed according to the 
data encountered: for categorical data, such as gender, Fisher’s 
exact or χ2 testing was performed. For continuous data, Welch’s 
t- tests were used if the assumptions of normality were met; other-
wise, non- parametric Mann- Whitney U tests were employed. In 
edge cases, permutation testing was performed. Two- sided statis-
tical significance was set at p<0.05, with Bonferroni correction 
for multiple testing.
Model development
Candidate laboratory variables were triaged for inclusion based 
on their membership of core or extended laboratory test panels, 
before a data- driven approach was applied. This included assess-
ment of variability, individual p values corrected for multiple 
comparisons and multicollinearity with generation of a Spear-
man’s rank correlation matrix.
Logistic regression, support vector machines, random forest 
and gradient boosted trees were all considered for multivar-
iate predictive models. Models with complexity greater than 
logistic regression were found to offer little improvement (data 
not shown). Multivariate logistic regression was implemented 
in Python (V.3.7) using the Scikit- Learn package (V.0.23)23 and 
Statsmodels (V.0.11). Complete case analysis was conducted to 
enable meaningful comparison between core and extended tests.
To minimise bias, models were evaluated using cross- validation 
with fivefolds, with stratification to account for class imbalance. 
Performance statistics are reported as the average across all folds 
with binomial proportion 95% CIs. Model discrimination was 
assessed by area under receiver operating characteristic curve 
(ROC AUC), accuracy (balanced by support) and weighted F1 
score (the average F1 score was calculated for each class and 
weighted by support). In addition to these performance metrics, 
threshold- performance curves were generated to assess the effect 
of the decision threshold on model sensitivity and specificity.24 
Source code for all models can be found on GitHub: https:// 
github. com/ burtonrj/ Card iffC ovid Biom arkers
Our evaluation is reported using the transparent reporting 
of a multivariable prediction model for individual prognosis or 
Figure 1 Study flow chart.
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diagnosis (TRIPOD) guidance for Prediction Model develop-
ment and validation (see online supplemental file 1).
Patient involvement
These data were generated as part of a rapid service improve-
ment and as such patients were not involved in the setting of the 
research question or interpretation of the study.
RESULTS
Definition and overview of service evaluation cohort
We focused on admissions occurring after the operational 
roll- out of the first extended laboratory test panel components 
into standard clinical practice. During this 105- day period, over 
13 500 ED attendances were recorded. Of these, 391 adults 
were admitted via ED with a laboratory- confirmed diagnosis of 
COVID-19 meeting our definition of likely community- acquired 
COVID-19 (figure 1). The median age was 69 years (IQR: 55–75 
years) with males predominant (52.4%). Within 28 days of index 
ED attendance, 113 deaths occurred (29% mortality), and 151 
patients reached the composite secondary endpoint of intensive 
care admission/death (39%).
Univariate analysis of laboratory predictors of adverse inpatient 
course
We next analysed the association between individual candidate 
variables and patient outcomes to identify important predictors of 
adverse outcome. Admission clinical variables are presented in table 1 
(for full dataset, online supplemental files S1, S2). Advanced age was 
strongly associated with increased risk of death and the composite of 
ICU admission and death. In contrast, neither gender nor socioeco-
nomic deprivation were associated with 28- day mortality. For labora-
tory variables, missing data were rare for core test panel components. 
Within the extended testing panel, hs- Trop and D- dimer were avail-
able in 70%–80% of patients admitted with COVID-19 within the 
Table 1 Demographic and selected clinical laboratory predictor variables on admission for evaluation cohort
Variable
Survivors (n=278) Non- survivors (n=113)
P valueFrequency (n (%)) % missing Frequency (n (%)) % missing
Gender 0.0 0.0
  Male 141 (50.7) – 64 (56.6) – 0.316†
  Female 137 (49.3) – 49 (44.4) –
WIMD* 2.5 0.9 0.228†
  Quartile 1 (<246) 65 (23.4) – 29 (25.6) –
  Quartile 2 (246 – 871) 61 (21.9) – 35 (31.0) –
  Quartile 3 (872–1672) 73 (26.3) – 23 (20.4) –
  Quartile 4 (>1672) 72 (25.9) – 25 (22.1) –
  Median (IQR) Median (IQR)
Age, years 63.5 (51.3–77.8) 0.0 81.0 (71.0–88.0) 0.0 <0.0001
’Core’ test component Median (IQR)
  Albumin, g/L 33.0 (29.0–36.0) 3.2 29.0 (26.0–32.0) 1.8 <0.0001
  Alkaline phosphatase U/L 80.0 (63.0–111.5) 0.0 100.0 (76.0–133.5) 0.0 0.0006
  Alanine transaminase U/L 27.0 (17.0–46.0) 0.0 23.0 (14.0–32.0) 0.0 0.256
  Bilirubin μmol/L 10.0 (7.0–15.0) 0.0 12.0 (8.0–17.0) 0.0 0.0018
  C reactive protein, mg/L 70.5 (21.0–131.8) 0.0 98.0 (55.75–164. 8) 2.6 0.005
  Creatinine, µmol/L 82.0 (66.0–105.0) 0.4 111.0 (79.0–192.0) 0.0 <0.0001
  Estimated glomerular filtration rate
  (eGFR) mL/min/1.73 m2
75.0 (55.0–89.0) 0.0 51.0 (25.0–74.0) 0.0 <0.0001
  Globulin g/L 38.0 (34.0–42.0) 0.1 40.0 (36.0–45.75) 0.1 0.0161
  Haemoglobin g/L 135.0 (122.0–149.0) 0.0 135.0 (122.0–149.0) 0.0 0.036
  Lymphocyte count ×109/L 1.0 (0.7–1.4) 0.0 0.9 (0.6–1.2) 0.0 0.961
  Neutrophil count ×109/L 5.4 (3.7–8.0) 0.0 7.3 (4.6–9.8) 0.0 0.017
  Neutrophil:lymphocyte ratio 5.25 (3.3–9.8) 0.4 8.11 (4.3–14.5) 0.9 0.011
  Platelet count ×109/L 234.0 (183.8–294.5) 0.0 216.0 (160.0–285.0) 0.0 0.210
  Potassium mmol/L 3.9 (3.6–4.3) 0.0 4.1 (3.7–4.6) 0.0 0.0006
  Protein g/L 71.0 (67.0–76.0) 0.1 70.0 (65.0–74.0) 0.1 0.04
  Sodium mmol/L 137.0 (134.0–139.0) 0.0 138.0 (134.0–141.0) 0.0 <0.0001
  Urea mmol/L 5.7 (4.0–8.5) 0.4 10.2 (7.2–16.2) 0.0 <0.0001
  White cell count ×109/L 7.35 (5.3–9.9) 0.0 9.0 (6.4–12.3) 0.0 0.016
’Extended’ test component
  Ferritin μg/L 325.0 (125.0–828.0) 57.9 482.0 (245.5–993.5) 54.9 0.395
  High- sensitivity D- dimer μg/L 926.5 (587.75–1750.0) 28.1 1497.0 (929.0–3885.0) 30.1 0.0003
  High- sensitivity troponin I ng/L 7.0 (3.0–23.0) 24.8 35.5 (15.75–117.0) 22.1 <0.0001
  Lactate dehydrogenase U/L 349.5 (270.3–549.8) 53.2 383.5 (290.5–501.3) 54.0 0.999
  Procalcitonin μg/L 0.14 (0.1–0.4) 41.4 0.31 (0.1–0.9) 38.9 0.019
Variables captured in the summarised cohort of community- acquired PCR- confirmed COVID-19 cases admitted through the Emergency Department between 17 March 2020 and 
30 June 2020. Summary statistics are given as the median and range for continuous variables and absolute counts for discrete variables. *Welsh index of multiple deprivation, 
WIMD, is ranked from 1 (most deprived) to 1909 (least deprived) and presented as frequencies within each quartile. †Fischer’s exact test.  on M
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first 72 hours of ED attendance. An early admission PCT test result 
was available in 40% of patients, while ferritin and LDH levels were 
recorded in 42%–46% of cases. Testing rates were similar between 
patient survival groups.
In univariate analysis of the core laboratory panel compo-
nents, increased CRP, neutrophil:lymphocyte ratio, urea, creat-
inine or decrease in serum albumin were all strongly associated 
with risk of death. Within the extended panel, D- dimer, hs- Trop 
and PCT differed between survivors and non- survivors on 
univariate analysis (figure 2; online supplemental file S3). No 
extended panel members were associated with development of 
the composite outcome (online supplemental files S4, S5). Age 
was associated with several variables (online supplemental file 
S6), indicating it could confound the relationship between a test 
result and mortality.
Development of prognostic model based on core and extended 
laboratory admission test panels
We therefore used multivariate logistic regression to adjust for 
the role of age, while controlling for gender and WIMD, based 
on consistent identification of their contribution to outcomes in 
COVID-19 cohorts.21 25 Restricting to cases with complete data 
(n=130) across core and extended laboratory tests, we found an 
optimal combination of core test variables to be CRP, albumin, 
urea, neutrophil:lymphocyte ratio, creatinine, age, gender and 
WIMD (figure 3, online supplemental file S7). This gave a prog-
nostic AUC of 0.79 (95% CI 0.67 to 0.91) for 28- day mortality 
and 0.70 (95% CI 0.56 to 0.84) for the composite outcome.
We next assessed the discriminative value associated with 
inclusion of extended panel components within our multivar-
iate model, relative to this core test set (figure 3). Addition of 
D- dimer resulted in a marginal increase in mean AUC score to 
0.82, but this was not significantly different (95% CI 0.71 to 
0.85) to the performance of core testing alone. Concerning the 
composite outcome, addition of admission hs- Trop to the core 
panel resulted in the greatest AUC score: 0.72 (95% CI 0.60 
to 0.83), but again, this did not represent a significant increase 
in performance to the core panel alone (online supplemental 
file S8). Consideration of extended test components individu-
ally or in combination did not improve on this. To internally 
Figure 2 Laboratory test results according to survival outcome and grouped by gender. Box and swarm plots showing the initial laboratory 
test results from laboratory- confirmed patients with COVID-19, grouped by gender and 28- day mortality. Example variables considered from the 
components of the core laboratory test panel. *Indicates level of significance, assessed by Mann- Whitney U test with correction for multiple testing: 
*P<0.05, **p<0.01, ***p<0.005, ****p<0.001.
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validate these findings, we performed stratified cross- validation, 
observing convergence of training and validation curves, thus 
suggesting a low- risk of overfitting associated with these models 
(online supplemental file S9, S10). Assessing the calibration of 
these models across a range of performance metrics by varying 
the decision threshold (the probability at which a patient is 
predicted to either die or be admitted to intensive care), we 
found no significant benefit from addition of the extended rela-
tive to the core laboratory testing panel online supplemental file 
S11, S12). Adjusted ORs for the individual contribution of each 
variable to the prediction of 28- day mortality and composite 
outcome are presented in online supplemental file S13. For both 
outcomes, the additional variables included in the extended 
panel provide little influence over the predicted outcome.
Patterns of extended panel requesting during the first wave
Local cost estimates for NHS requesting the core laboratory panel 
totalled £16.44 per patient, with an additional £55.48 incurred 
for the extended set (online supplemental file S14). In order to 
contextualise testing beyond the cohort of community- acquired 
COVID-19, we constructed a run chart of test requesting within 
the first 72 hours of admission via ED and COVID-19 related 
admissions (figure 4). D- dimer and hs- Trop testing rates rose in 
line with COVID-19 admissions during March and April, with a 
1–2 week delay apparent for LDH, ferritin and PCT requesting. 
Strikingly, while COVID-19 admissions declined following the 
April peak, the intensity of extended biomarker panel requesting 
remained. Using January and June 2020 to represent requesting 
patterns before and after the first wave of COVID-19, mean 
monthly requesting increased by 29.7%, 224% and 588% for 
hs- Trop, ferritin and LDH, respectively. In contrast, recorded 
monthly ED attendance fell by 24.0% over this period. PCT and 
quantitative D- dimer were specifically introduced in response to 
the pandemic but still averaged >50 daily test requests within 
the early admission period during June. Across the evaluation 
period, over 6400 D- dimer and 5400 PCT requests were made, 
with an estimated service cost of £246 000.
DISCUSSION
To support the effective and efficient use of resources through 
evidence- based clinical practice, we conducted a service evalua-
tion determining the prognostic value associated with routinely 
performed laboratory investigation in 130 adults admitted with 
community acquired SARS- CoV-2 infection. By leveraging a 
bespoke electronic healthcare registry, we reveal an extended 
panel (including D- dimer, LDH, hs- Trop, ferritin and PCT) 
provided only limited additional prognostic information beyond 
that provided by components of the core panel (FBC, U&E, 
LFT and and CRP). Together, this directs refinement of the clin-
ical testing panel employed before and during future potential 
waves, underlining the relevance of this registry approach to 
support cost- utility of investigation pathways.
We identified five studies within the peer- reviewed and 
preprint literature concerning laboratory biomarker risk strat-
ification of adult COVID-19 admissions in the UK popula-
tion.4 17–20 The largest reported, an 8- point pragmatic risk score 
Figure 3 Prognostic performance of core and extended laboratory markers. Balanced accuracy (A), weighted F1 score (B), AUC score (C) and ROC 
curves (D) for models with sequential inclusion of extended biomarkers for prediction of 28- day mortality. AUC, area under the curve; LDH, lactate 
dehydrogenase; PCT, procalcitonin; ROC, receiver operating characteristic.
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developed by the International Severe Acute Respiratory and 
Emerging Infection Consortium (ISARIC), achieved a modest 
AUC performance score of 0.77 (95% CI 0.76 to 0.77) when 
predicting 28- day mortality.19 To date, only one UK study has 
considered the prognostic role of variables within our extended 
laboratory panel.18 In their prospective analysis of 155 patients, 
Arnold et al18 found conventional laboratory biomarkers such as 
CRP and neutrophil elevation offered limited prognostic perfor-
mance (with AUC scores of 0.52 and 0.54, respectively), while 
ferritin, PCT, hs- Trop and LDH performed with AUC scores 
of 0.65 to 0.71. It is important to note that within this study 
cohort, the incidence of clinical deterioration was low (overall 
mortality was only 4% vs 29% for our service evaluation), which 
may have limited the power of the study. This highlights regional 
variation in rates of hospitalisation and mortality and further 
motivated a locally led assessment of practice.
Consistent with the emerging COVID-19 literature, we 
observed an association between laboratory markers of acute 
phase inflammatory response (elevated neutrophil count, CRP, 
depressed lymphocytes and albumin), cardiac injury, activation 
of thrombosis and renal impairment with subsequent adverse 
outcome.6 21 26 We found a combination of CRP, albumin, urea, 
neutrophil:lymphocyte ratio and creatinine alongside simple 
demographics achieved an AUC of 0.79 (95% CI 0.67 to 0.91) 
when predicting 28- day mortality and 0.70 (95% CI 0.56 to 0.84) 
for the composite endpoint. Importantly, we found no evidence 
that use of this panel at admission significantly improved perfor-
mance for either outcome, consistent with international reports 
revealing limited value of admission and serial D- dimer testing 
with regard to prognostic yield.27 Addition of the extended 
laboratory test panel equates to £54 per patient (a relative cost 
increase of over 400% to the core panel alone), with significant 
cost ramifications when performed at scale. At a local level, we 
also identified use of the extended laboratory panel continued 
despite falling rates of COVID-19 presentations, allowing feed-
back to requesting teams and directly changing practice.
Our service evaluation has several strengths, notably assess-
ment of the performance of an extended panel of laboratory 
tests not widely considered in UK prognostic studies to date 
within a clinical cohort identified based on commonly used 
clinical and virological criteria.4 17–20 Laboratory tests were 
integrated into routine practice prior to the local peak of the 
pandemic based on available literature and national guidelines.15 
In contrast with the batched analysis undertaken under research 
condition in previous studies,18 all tests described here were 
conducted by accredited laboratories using platforms calibrated 
to international reference standards, facilitating future data 
sharing. Our multivariate approach is well suited to investigate 
whether specific laboratory tests provide additional prognostic 
value beyond conventional parameters,28 using inclusion criteria 
and clinically relevant endpoints in line with other reported 
studies.4 17 19 Finally, we considered the service costs that accom-
panied implementing these tests into routine practice,29 a rele-
vant factor often neglected in other publications.
Our evaluation also has a number of limitations, reflecting 
the challenges of clinical data collection during an epidemic. 
It represents retrospective experience from a single tertiary 
referral centre, limiting sample size. However, the study 
cohort inclusion criteria reflected national admission criteria 
for COVID-19 that remain active as the UK enters the next 
Figure 4 Daily COVID-19 admission rates and test requesting patterns during the early admission period. Run chart showing emergency unit (EU) 
admission rates for patients with confirmed laboratory- confirmed COVID-19 (right y- axis, dashed- line) and accompanying tests performed within 72 
hours of emergency department attendance (left y- axis, solid- line) during the first wave of the COVID-19 pandemic. The dotted line indicates the roll- 
out of extended panel testing from 17 March 2020.
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wave of COVID-19, highlighting the likely wider relevance 
of these findings. Second, availability of extended test 
panel results during the early admission period was mixed. 
Admission D- dimer and hs- Trop results were available for 
70%–80% of patients, comparing favourably to a similar 
UK registry- based study where D- dimer results were only 
available at time of admission in 37.2%.17 Conversely, we 
observed high rates of missing data for LDH, ferritin and 
PCT, undermining their relevance as a prognostic tool. This 
was likely due to operational factors such as a delay in test roll 
out relative to epidemic peak, and requirement for an addi-
tional sample tube. Because it cannot be assumed that data 
are missing at random, we chose to perform complete case 
analysis. Although this limits our statistical power, it avoids 
unfounded assumptions and potentially invalid imputation. 
In its current form, the CHoRD registry lacks detailed infor-
mation on patient- level physiological observations, nature of 
comorbidities, cause of death and therapeutic interventions. 
Similarly, all registry- linked laboratory values were available 
to clinicians and are likely to have influenced management 
decisions. Advances in clinical care diagnostics, therapeutics 
and potentially viral mutation are likely to alter the observed 
performance of the prognostic model. These limitations apply 
equally to pragmatic risk- scores,4 18 19 and the utility of risk 
stratification tools may vary over time.30 Finally, we recognise 
our evaluation consider the index test result and a specific 
question of inpatient prognosis, and additional indications 
exist for requesting components of the extended laboratory 
tests that fall outside of our primary and secondary endpoints. 
For instance, the use of PCT is often employed to support anti-
biotic stewardship31 and was integrated into routine practice 
locally in early April 2020. There may also be merit in more 
targeted use of additional testing. For example, a combination 
of routine and extended laboratory blood tests have recently 
been shown to support prediction of SARS- CoV-2 infection32; 
however, the cost- efficacy relative implementation of serial 
universal PCR screening remains uncertain. Hence, while 
we highlight the significant associated healthcare costs with 
implementation of extended laboratory testing, we do not 
make specific claims concerning the potential savings from 
discontinuing unnecessary investigations.29
Implications for practice
Laboratory markers supporting early risk stratification of 
patients are often used in the ED setting and have been shown to 
benefit patient triage.33 Our data suggest that systematic testing 
of COVID-19 positive patients on admission with an ‘extended’ 
laboratory panel provide little additional prognostic information 
for COVID-19 mortality or intensive care admission ‘core’ tests. 
Besides the financial impact, over- requesting of laboratory tests 
are likely to increase the number of false- positive results, with 
the potential to lead to further potentially harmful tests (eg, CT 
pulmonary angiography in patients with marginally elevated 
D- dimer but no clinical indication of thromboembolic disease).34 
We suggest that the use of these laboratory markers be targeted 
to patients with specific clinical indications for these, such as 
PCT to guide antibiotic prescription or hs- Trop in patients with 
suspected myocardial injury.
In conclusion, we report our real- world experience from the 
use of an extended laboratory prognostic testing panel in patients 
hospitalised with community- acquired COVID-19. These find-
ings directly inform clinical practice, guiding cost- efficient use 
of resources in potential future waves.
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 ► Besides the financial impact, over- requesting of laboratory 
tests are likely to increase the number of false- positive 
results, with the potential to lead to further potentially 
harmful investigations (eg, CT pulmonary angiography in 
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indication of thromboembolic disease). We suggest that the 
use of these laboratory markers be targeted to patients with 
specific clinical indications for these, such as procalcitonin to 
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suspected myocardial injury.
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